DeCODE Genetics has made significant strides in precision health with a large-scale study, uncovering genetic variants linked to various diseases. This breakthrough has paved the way for more accurate diagnosis and treatment.
The study analyzed genetic data from over 160,000 Icelanders, revealing over 10 million genetic variants. This wealth of information has been used to identify genetic risk factors for conditions such as heart disease, type 2 diabetes, and certain types of cancer.
DeCODE Genetics' study has shown that genetic data can be used to predict an individual's risk of developing certain diseases, allowing for early intervention and prevention. This is a major step forward in the field of precision health.
Take a look at this: Veritas Genetics
Iceland and Population Approach
Iceland was the perfect place for deCODE to start its population approach, with a relatively small population of 270,000 people at the time.
The country's unique characteristics made it an ideal location for the company's ambitious plans. deCODE's founder, Kari Stefansson, believed that Iceland fit the description of having a population willing to participate in research, a modern healthcare system, and comprehensive genealogical data.
Expand your knowledge: Pensions in Iceland
In 1996, deCODE set up a laboratory in Iceland and began operations with $12 million in funding from American venture capital.
Within a few years, the company recruited and genotyped tens of thousands of participants, making rapid progress in creating a national genealogy database.
deCODE developed a novel privacy protection system with government-supervised identity encryption to safeguard participants' sensitive information.
The company also signed a landmark partnership with Swiss pharmaceutical company Roche and made significant progress in mapping putative disease genes in various conditions.
Scientific Discoveries
DeCODE genetics has made some groundbreaking discoveries in the field of genetics. Their research has led to a better understanding of the genetic factors that contribute to common diseases.
The company's work on the genetic basis of type 2 diabetes has been particularly significant. They identified 12 genetic variants that increase the risk of developing the disease.
One of these variants is associated with a 50% increased risk of developing type 2 diabetes. This is a remarkable finding that highlights the importance of genetics in disease susceptibility.
DeCODE genetics has also made significant contributions to the field of cardiovascular disease. They identified a genetic variant that increases the risk of heart attack by 50%.
Additional reading: Investment Fund for Developing Countries
Business
Amgen acquired deCODE Genetics for $415 million in an all-cash transaction. This was a significant move for the company, as it expanded its capabilities in human genetics.
deCODE Genetics was founded in 1996 and has a strong reputation for analyzing the link between the genome and disease susceptibility. The company has discovered genetic risk factors for dozens of diseases, including cardiovascular disease and cancer.
The acquisition was a strategic move for Amgen, as it aimed to enhance its efforts in identifying and validating human disease targets. This will enable the company to develop relevant molecules that target specific diseases more effectively.
Kari Stefansson, the founder and CEO of deCODE Genetics, believed that Amgen's focus and ability to incorporate genetic research into drug development efforts would translate discoveries into meaningful therapies for patients.
Suggestion: Amgen Fortune 100
Frequently Asked Questions
When did Amgen buy deCODE?
Amgen acquired deCODE in December 2012 for $415 million. This marked a significant expansion of Amgen's genetic research capabilities.
Featured Images: pexels.com
